Literature DB >> 29602914

Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab.

Mika Saarela1, Keerthi Senthil1, Joanne Jones1, Pentti J Tienari1, Merja Soilu-Hänninen1, Laura Airas1, Alasdair Coles1, Jukka T Saarinen2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29602914     DOI： 10.1212/WNL.0000000000005420

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  16 in total

Review 1.  Established and Emerging Immunological Complications of Biological Therapeutics in Multiple Sclerosis.

Authors:  Babak Soleimani; Katy Murray; David Hunt
Journal:  Drug Saf       Date:  2019-08       Impact factor: 5.606

2.  Intrathoracic infections in Hodgkin lymphoma (HL) patients may cooperate with HL to trigger hemophagocytic lymphohistiocytosis: A retrospective study.

Authors:  Ji-Cheng Zhou; Bin-Bin Tan; Yan Huang; Yin-Ying Wu; Zhen-Jie Bai; Min-Lan Liang; Wei-Hua Zhao
Journal:  Medicine (Baltimore)       Date:  2022-07-01       Impact factor: 1.817

Review 3.  Managing Risks with Immune Therapies in Multiple Sclerosis.

Authors:  Moritz Förster; Patrick Küry; Orhan Aktas; Clemens Warnke; Joachim Havla; Reinhard Hohlfeld; Jan Mares; Hans-Peter Hartung; David Kremer
Journal:  Drug Saf       Date:  2019-05       Impact factor: 5.606

Review 4.  Role of Monoclonal Antibody "Alemtuzumab" in the Treatment of Multiple Sclerosis.

Authors:  Sadia Nosher; Sehrish Fuad; Nupur Mishra; Zaid A Alrashid; Bindu Rathod; Devyani Mohan; Deepak M Basavanagowda; Arveen Kaur; Stacey E Heindl
Journal:  Cureus       Date:  2021-02-09

Review 5.  Hemophagocytic lymphohistiocytosis with immunotherapy: brief review and case report.

Authors:  Masood Sadaat; Sekwon Jang
Journal:  J Immunother Cancer       Date:  2018-06-05       Impact factor: 13.751

6.  Emerging safety issues in alemtuzumab-treated MS patients.

Authors:  Joep Killestein; Bob van Oosten
Journal:  Mult Scler       Date:  2019-08       Impact factor: 6.312

7.  Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis.

Authors:  Trygve Holmøy; Børre Fevang; David Benee Olsen; Olav Spigset; Lars Bø
Journal:  BMC Res Notes       Date:  2019-08-12

8.  Case Report: Adult Still's Disease in an Alemtuzumab-Treated Multiple Sclerosis Patient.

Authors:  Julia Krämer; Tanja Krömer-Olbrisch; Heinz-Jürgen Lakomek; Peter D Schellinger; Dirk Foell; Sven G Meuth; Vera Straeten
Journal:  Front Immunol       Date:  2020-08-28       Impact factor: 7.561

9.  Vitamin D supplementation for the prevention or depletion of side effects of therapy with alemtuzumab in multiple sclerosis.

Authors:  Hans-Klaus Goischke
Journal:  Ther Clin Risk Manag       Date:  2019-07-12       Impact factor: 2.423

10.  Pretreatment anti-thyroid autoantibodies indicate increased risk for thyroid autoimmunity secondary to alemtuzumab: A prospective cohort study.

Authors:  Tobias Ruck; Andreas Schulte-Mecklenbeck; Steffen Pfeuffer; Michael Heming; Luisa Klotz; Susanne Windhagen; Christoph Kleinschnitz; Catharina C Gross; Heinz Wiendl; Sven G Meuth
Journal:  EBioMedicine       Date:  2019-07-29       Impact factor: 8.143
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.